COVID-19 vaccine recommendations could be changing, according to the U.S. Food and Drug Administration. FDA leaders said on May 20 that clinical trials will be required to approve annual COVID-19 ...

Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus ...

In a large, randomized trial, researchers at Mass General Brigham have found that high-dose vitamin D3 did not reduce COVID-19 infection severity, but may impact long COVID outcomes.

Researchers say a medication originally used for epilepsy may significantly reduce breathing interruptions in people with sleep apnea, raising the possibility of a pill-based treatment.

Researchers are still trying to understand why some people develop Long COVID: lasting symptoms of the disease that can ...

Vitamin D didn’t blunt COVID’s initial impact—but it may hold a surprising clue in the fight against long COVID.

In a large, randomized trial, researchers at Mass General Brigham found that high-dose vitamin D3 did not reduce COVID-19 ...

Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution. Researchers ...

In this week’s edition of InnovationRx, we look at the richest five healthcare billionaires, Lilly’s first big AI success, Science Corp.’s brain implants, and more.

Some members of the CDC’s vaccine advisory panel have publicly questioned the safety and manufacturing of the shots, including raising a debunked theory that DNA contaminants in the vaccines are ...

A futuristic “DNA origami” vaccine platform may one day outperform mRNA shots while being easier to produce and distribute. Credit: Shutterstock Scientists have developed a new DNA origami–based ...

The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...